The Noida Commercial Court has maintained an injunction against four Indian pharma companies for illegally producing and exporting pharmaceuticals based on Jubilant Generics Limited's proprietary information. The decision strengthens copyright protection for Jubilant's confidential product dossiers, preventing unauthorized use, production, and exports.

Key Highlights:
Court Decision on Copyright Protection
The court upheld an injunction against:

• Medreich Limited

• V S International Private Limited

• Gracure Pharmaceuticals Limited

• Jamp India Pharmaceuticals Private Limited (a subsidiary of Jamp Pharma Corporation, Canada)

These organizations were convicted of pirating Jubilant's trade secrets, proprietary technology, and copyrighted product dossiers.

Products Involved in the Copyright Infringement
The infringing drugs were:

• Losartan (for high blood pressure)

• Citalopram (antidepressant)

• Amlodipine (for high blood pressure and heart disorders)

The firms were discovered to be producing, supplying, and exporting these medicines illegally, mainly to Jamp Pharma in Canada.

Role of Allahabad High Court

• The Allahabad High Court had previously instructed the Commercial Court to hear the case and make clear copyright protection on Jubilant's product dossiers.

• As the court heard the case, it did not interfere with the injunction against the defendants.

Legal Strategies of Defendants and Rejected Appeals

• The Canadian firm Jamp Pharma has refuted collusion with the Indian companies but could not establish non-involvement.

• The defendants filed several legal efforts to vacate the injunction, claiming that Jubilant's dossiers were not covered by copyright law.

• The court ruled in favor of Jubilant despite their attempts, upholding full copyright protection over its proprietary product dossiers.

Court's Final Ruling:
The Commercial Court's order strictly inhibits the defendants from:

• Reproduction or use of Jubilant's copyrighted product dossiers in any manner.

• Production, distribution, or export of the mentioned pharmaceuticals.

• Disclosure of confidential information pertaining to Jubilant's dossiers to third parties.

Quotes of Jubilant Legal Representative:
Sanjay Gupta, Legal Head, Jubilant Generics Limited:

• "The well-reasoned order of the court has acknowledged Jubilant's compelling case for the protection of its intellectual property."

• "The ruling establishes that our product dossiers are copyrighted and cannot be used or reproduced without authorization."

The Noida Commercial Court decision solidifies intellectual property rights in India's pharma sector. Jubilant's win in court serves as a precedent in defending proprietary drug designs, preventing copyright infringement from going unpunished. The court decision upholds the need to protect innovation and proprietary research in the pharma sector.